PHARMA HORIZONS

Pharma Horizons: Artificial Intelligence

Shares

33

Share this post

EPR‘s inaugural Pharma Horizons report explores the latest advances in artificial intelligence (AI) and machine learning (ML) for drug development, pharmaceutical manufacturing and quality control.

AI/ML is predicted to be the top technology investment for 60 percent of life sciences companies over the next two years, according to a recent survey1 from the Pistoia Alliance. Additionally the pharmaceutical AI market is projected to reach $11.8 billion by 2032, driven by its ability to enhance manufacturing, clinical trials, and research & development.

Register now to access this exclusive content as we delve into some of the challenges and opportunities for AI in pharma, with exclusive insight from:

  • Dr Feng Ren, Chief Scientific Officer and Head of R&D at Insilico Medicine 
  • Dr Andrew Hopkins, founder of Exscientia, a company that brought four AI-generated drugs into the clinic in 2023
  • Tero Laulajainen, Head of Global Clinical Science at UCB
  • Vincenzo Salvatore, Legal Expert from BonelliErede 
  • Dr Tim Sandle, Microbiology expert 
  • Phoebe Clough, experienced QP.  

Stay abreast of the latest developments in AI and ML with articles including:

  • Augmenting clinical trials with AI
  • Enhancing contamination control methods: how AI is shaping microbiology and QP oversight
  • Leveraging generative AI in quality control
  • Exchanging trial and error for transformative technology.

Interested? Register your details now to download for free today!

Share via